Binding to fibronectin (FN)--a prerequisite step? Investigations on the role of FN in intravesical BCG immunotherapy.
Böhle
A
A
Klinik und Poliklinik für Urologie, Medizinische Universität zu Lübeck.
van der Sloot
E
E
Richter
E
E
Gerdes
J
J
Wood
W G
WG
Jocham
D
D
D000283:Administration, Intravesical; D000906:Antibodies / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism*; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D005353:Fibronectins / Q000276:immunology / Q000378:metabolism* / Q000652:urine; D006801:Humans; D007249:Inflammation; D008163:Luminescent Measurements; D008863:Microspheres; D009504:Neutrophils / Q000201:enzymology / Q000502:physiology; D010793:Phthalazines; D001743:Urinary Bladder / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism
D000906:Antibodies; D001500:BCG Vaccine; D005353:Fibronectins; D010793:Phthalazines; D014613:Vaccines, Attenuated; C066306:9-(N-(4-aminobutyl)-N-ethyl)aminobenzo(f)phthalazine-1,4-(2H,3H)dione